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Sl~1"Ellrlary 
We have recently shown that the human antibody response to the hepatitis B virus surface antigen 
(HBsAg) vaccine is major histocompatibility complex (MHC) associated. In studies of nonresponders 
to the vaccine, we found an increased incidence  of individuals homozygous for human histo- 
compatibility leukocyte antigen (HLA) proteins associated with the extended (conserved) haplotype 
[HLA-BS,SC01,DR3]. In later prospective vaccination trials, we showed that none of five individuals 
homozygous for this haplotype developed more than 1,300 radioimmunoassay (RIA) units of 
antibody (mean, 467 RIA units), while all heterozygotes made at least 2,500 RIA units (mean 
antibody level, 15,608 units). Our results suggested that [HLA-B8,SC01,DR3] lacks an immune 
response gene for HBsAg, and that response is inherited in a dominant fashion. To provide further 
evidence for this hypothesis, we have now analyzed the results of HBsAg immunization in families. 
43 members of 10 families were immunized with the hepatitis B vaccine, including seven families 
where at least one member bore the haplotype [HLA-BS,SC01,DR3], and three families where 
one member had already received, but failed to respond to,  the vaccine. In two of these three 
families, the presence of [HLA-BS,SC01,DR3] was subsequently found. Of nine MHC-identical 
sibling pairs in the study, both members of eight pairs had similar  antibody responses  (five 
nonresponder and three responder pairs).  In all families with such sibling pairs, including the 
discordant pair, rank-ordering members by antibody level demonstrated that no relative's value 
came between the sibling pair values. Furthermore, of nine [HLA-BS,SC01,DR3]-haplotype- 
homozygous individuals, six were nonresponders, and two others had only low-normal responses. 
[HLA-BS,SC01,DR3]-heterozygous family members always had higher levels of antibody than 
their homozygous relatives. Linkage analysis of nonresponse to HLA haplotypes revealed  a maximum 
likelihood LOD (logarithm of the odds) score of 6.3 at a recombination fraction of 0.1. The 
MHC association with lack of antibody response to HBsAg was not seen with tetanus immuni- 
zation, where 1 of 20 HBsAg responders and 1 of 21 poor or nonresponders had tetanus titers 
of <1:512; both tetanus nonresponders were [HLA-B8,SC01,DR3] heterozygotes. Our results 
indicate that: (a) response to the HBsAg vaccine is MHC linked, and inherited in a dominant 
fashion;  (b) an abnormal or missing immune response (Ir) gene for HBsAg is a characteristic 
of most examples of the extended haplotype [HLA-B8,SC01,DR3];  and (c) other haplotypes 
also have abnormal or missing Ir genes for HBsAg. 
T 
he immune response in mice to a variety of protein an- 
tigens is determined by class II genes of the MHC (1). 
The identification of relationships between murine H-2 gene 
complexes and the ability to recognize specific antigens has 
been facilitated by the use of inbred and H-2 congenic mouse 
strains, and their recombinant variations, in in vivo immuni- 
zation experiments. For example, the response to the surface 
polypeptide antigen of the hepatitis B virus (HBsAg) 1 has 
been shown to be linked to MHC class II genes. Mice with 
the H-2  f and H-2  s haplotypes produce negligible titers of 
anti-HBs after immunization with the HBsAg vaccine (in 
1  Abbreviations used in this paper: HBsAg, hepatitis B virus surface antigen; 
HBV, hepatitis  B virus; It, immune response. 
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while other strains produce either intermediate (H-2  b, H-2  k) 
or high (H-2  a, H-2q) levels (2). F1 hybrids respond normally 
to the hepatitis vaccine provided that one parent is a responder 
(3). No evidence has been uncovered for HBsAg suppressor 
cells in nonresponder strains (4). These experiments have es- 
tablished the presence, in responder mice, and absence in non- 
responders, of one or more dominant immune response (Ir) 
genes related to formation of antibody to HBsAg, although 
their precise location within the MHC remains unknown. 
The murine and human MHC share many common fea- 
tures.  However,  identification  of specific  MHC  genes  in 
humans  related to immune response has been considerably 
more dii~cult, because human populations are largely out- 
bred, and carry diverse HLA antigens reflecting the marked 
polymorphism  of this gene system.  Despite these impedi- 
ments, we have recently demonstrated that the human anti- 
body response to immunization  with the HBsAg vaccine is 
MHC associated.  Many clinical  studies have demonstrated 
that up to 7.5% of otherwise healthy HBsAg vaccine recipients 
are poor or nonresponders  (5-11).  In our initial  study of a 
group of such nonresponders,  we noted an increased inci- 
dence of individuals presumably homozygous (by phenotype) 
for the HLA class I gene HLA-B8, the class II gene HLA- 
DIL3,  and  the  genes for  the  complement  proteins  BF*S, 
C2"C, C4A*QO (a null gene), and C4B'1 (12). These MHC 
alleles are commonly inherited en bloc as an extended (con- 
served) haplotype, abbreviated [HLA-BS,SC01,DR3]. We and 
others have shown that in unrelated individuals with MHC 
markers for a number of different extended haplotypes, the 
genetic material along the entire area of the chromosome be- 
tween HLA-B and HLA-DR/DQ is relatively fixed (13-16); 
thus, extended haplotypes may be considered similar to the 
H-2 haplotypes of inbred  mice. 
To test in vivo the hypothesis that the extended haplotype 
[HLA-B8,SC01,DR3] might be associated with absence of 
an immune response gene for HBsAg, we immunized indi- 
viduals bearing this haplotype. 2 mo after the final injection, 
none of the five haplotype-homozygous subjects had >1,300 
ILIA U  of antibody (mean,  467 ILIA U), while all of the 
heterozygotes produced >2,500 RIA U  (mean,  15,608 U) 
(17). We concluded from these results that the extended haplo- 
type [HLA-BS,SC01,DR3], similar to nonresponder mouse 
haplotypes,  lacked an  immune  response gene for HBsAg. 
Furthermore,  our results  suggested  that  in  the  [HLA-B8, 
SC01,DR3] heterozygote responders, the immune response 
gene present on the other haplotype functioned in a domi- 
nant manner. To further characterize the inheritance pattern 
of the immune response to HBsAg in relation to the MHC, 
we now report the results of HBsAg immunization  studies 
in families. 
Materials and Methods 
Subjects.  Families  of subjects recruited for the immunization 
trial were from two sources: families where at least one individual 
bore the haplotype [HLA-BS,SC01,DR3] (seven famih'es), identified 
from a Center for Blood Research database of >10,000 MHC-typed 
individuals, and families where an individual member had failed 
to respond to a standard immunization  protocol with hepatitis B 
vaccine (three families). The results of hepatitis immunization  in 
some members of four families, who were either homozygous or 
heterozygous for the haplotype [HLA-BS,SC01,DR3], have been 
previously reported  (17). 
Vaccines and Antibody Determinations.  Hepatitis B vaccine, ini- 
tially plasma derived and later of recombinant origin, was kindly 
supplied by Merck,  Sharp & Dohme (Lancaster, PA). The im- 
munogenicity of the two sources of vaccine is identical (18); how- 
ever, for uniformity, all individuals in a family received either one 
or the other source of vaccine consistently. A standard vaccination 
protocol was used: 20/zg of vaccine was administered intramuscu- 
larly into  the deltoid at the start of immunization,  and again 1 
and 6 mo after the first dose. Antibody to HBsAg was determined 
by RIA (AUSAB; Abbott Laboratories, North Chicago, IL) and 
expressed as estimated RIA U. Antibody was measured before im- 
munization  and 2 mo after the last vaccine injection.  Antibody 
to HBc was determined by a competitive inhibition  enzyme im- 
munoassay (Corzyme; Abbott Laboratories). Individuals who had 
not received tetanus toxoid booster in the last 10 yr were offered 
reimmunization with tetanus toxoid. Anti-tetanus toxoid titers were 
determined by hemagglutination  inhibition. 
Histocompatibility Studies.  MHC markers were determined  in 
previously untested individuals as follows. Blood samples for com- 
plement typing were anticoagulated with EDTA, and the plasma 
and red cells were separated and frozen at  -80~  until thawed 
for analysis. For HLA class I and II markers, heparinized blood 
samples were diluted with equal volumes of RPMI 1640, after which 
lymphocytes were separated by Ficoll-Hypaque, frozen, and stored 
in vapor-phase liquid nitrogen  until thawed for analysis. Comple- 
ment types were determined by agarose gel electrophoresis for BF 
and C4, and isoelectric focusing for C2, as described previously 
(19-21). Complement  results are reported as the abbreviated com- 
pilation of the alleles BF, C2, C4A,  and C4B, in that arbitrary 
order. Serotyping for HLA-A, -B, -C, -DR, and -DQ was performed 
using standard National Institutes of Health microcytotoxicity tech- 
niques. 
Statistics.  Statistical  significance was determined using Fisher's 
exact test. Maximum  likelihood statistical analysis (logarithm  of 
the odds [LOD] scoring) was used to test for linkage between non- 
response to the hepatitis B vaccine and HLA haplotypes (22). For 
the purposes of this analysis, nonresponse was considered recessive, 
and the offspring from two-generarion families with the extended 
haplotype [HLA-BS,SC01,DR3] were scored as phase known with 
nonresponse linked to that haplotype. 
Resulu 
Study Enrollment.  43 members of 10 families were im- 
munized with the hepatitis B vaccine.  Families  A-E each in- 
cluded at least one member homozygous for the haplotype 
[HLA-B8,SC01,DR3]. Families F and G had members who 
were heterozygous for this haplotype, but no homozygous 
individuals. Families H, I, andJ each included a known vac- 
cine nonresponder.  The proband nonresponder in family J, 
an emergency medicine technician,  contracted hepatitis B 6 mo 
after the failed immunization attempt. He had a typical course 
for acute infection,  and made an uneventful recovery, with 
the  disappearance  from  his  serum  of the  surface antigen, 
HBsAg, and the appearance of antibody to the nudeocapsid 
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detected. 
Antibody Levels.  No antibodies  to HBsAg were detected 
in any subject before immunization. Antibody levels 2 mo 
after the last vaccine injection are shown in relation to each 
family's pedigree and HLA type (Fig. 1). Our previous study 
revealed a bimodal distribution of antibody response in normal 
vaccine recipients, with some overlap between nonresponder 
and responder  populations at antibody levels between 800 
and 2,000 RIA U  (17). Based on these data, subjects in the 
current study were considered nonresponders if antibody levels 
were <2,000 ILIA U, and normal responders if antibody levels 
were/>2,000  RIA U. 
Antibody Levels in HLA.identical Siblings.  If antibody re- 
sponse is linked to the MHC, antibody levels in HLA-identical 
siblings should be similar or identical.  Fig. 2 depicts  anti- 
body response in the 43 subjects,  and highlights nine pairs 
of HLA-identical siblings from eight families (including two 
from family H). In eight of nine pairs, both members made 
similar levels of antibody in response  to immunization: in 
five  pairs, both  individuals  were  nonresponders  (families 
A,C,U,  and one of the two pairs in H), and in three pairs, 
both were responders (families B,D, and G). Family H con- 
tained the only discordant pair, consisting of one individual 
who was a nonresponder,  and one with an exuberant anti- 
body response. Even including the discordant family H pair, 
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Fibre 1.  Family pedigrees. HLA markers  found on each haplotype are listed in the table below the pedigree. The extended haplotype [HLA-B8,SC01,DR3] 
is outlined. The number over each family member is the level of antibody to HBsAg  2 mo after the third injection. (O) Members with normal antibody 
response (;~2,000 RIA U); (e) nonresponders (<2,000 RIA U). ND, not vaccinated. *Proband nonresponder. 
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Figure  2.  Antibody  response 
versus presence of IHLA-B8,SCOI, 
DR31. (e) [HLA-BS,SC01,DR31 
homozygous;  (~) [HLA-B8,SC01, 
DR3]  heterozygous;  (O)  other 
haplotypes. Boxed points are HLA- 
identical sib-pairs. 
it can be seen in Fig. 2 that the HLA-identical sibling pairs 
always occur sequentially  in rank order by antibody level, 
without intervening haplo- or nonidentical relatives. Anal- 
ysis of concordance was carried  out using six of the seven 
families  with  a  nonresponder member (Table  1,  families 
A,B,C,E,I, and J; family H, with eight nonresponders, was 
excluded because it was not informative). In each of these 
six  families,  a vaccine  nonresponder (when possible,  one 
member of an HLA-identical pair) was compared against all 
other family members. This analysis revealed that all HLA- 
identical siblings were concordant (nonresponders), and 13 
of 14 haplo- or nonidentical siblings were discordant (anti- 
body responders) (p <  0.002 by Fisher's  exact test). 
Antibody Levels in [HLA-B8,SCOI,DR3] Halolotype-homo- 
zygous Individuals.  If nonresponse to the hepatitis B vaccine 
is associated with the [HLA-B8,SC01,DR3] extended haplo- 
type, and is due to the absence of an Ir gene on this haplo- 
type, haplotype-homozygous individuals should in general 
be nonresponders, and individuals heterozygous for this haplo- 
type should be responders,  provided that the other haplo- 
type contains a normally functioning Ir gene. This hypoth- 
esis is supported by the results shown in Fig. 2, where antibody 
response in relation to the HLA extended haplotype [HLA- 
BS,SC01,DR3]  is  shown.  In  families  A,  B,  and  C,  five 
extended-haplotype-homozygous  individuals (previously re- 
ported) were all antibody nonresponders (17), while eight 
heterozygotes made normal levels of antibody. Two [HLA- 
BS,SC01,DR3]-homozygous siblings in family D  did pro- 
duce antibody; however, the levels of antibody produced were 
at the low end of the normal range (2,180 and 7,860 RIA 
U), and distinct from the response of their haplotype-hetero- 
zygous sibling (330,400  RIA U).  Family E contained one 
[HLA-B8,SC01,DR3]  haplotype-homozygous  nonresponder, 
but  also the  only [HLA-B8,SC01,DR3]  homozygous in- 
dividual, out of the nine homozygous study subjects in five 
families, who responded vigorously to the hepatitis vaccine 
(44,800  RIA U). 
Table  1.  Concordance  of Antibody Response and HLA  Type 
Family  HLA type  Concordant  Discordant 
A  Identical  1  0 
Nonidentical  0  3 
B  Identical  0  0 
Nonidentical  0  5 
C  Identical  1  0 
Nonidentical  0  1 
E  Identical  0  0 
Nonidentical  0  1 
I  Identical  1  0 
Nonidentical  1  1 
J  Identical  1  13 
Nonidentical  0  2 
Total  Identical  4  0 
Nonidentical  1  13 
In six families with a vaccine nonresponder, each additional family mem- 
ber is categorized by comparison with the nonresponder based on HLA 
haplotype and antibody response. 
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for the [HLA-BS,SC01,DR3]  haplotype, but no homozygotes. 
All members of families F and G (seven individuals, including 
five heterozygotes for the haplotype) made normal levels of 
antibody to hepatitis B surface antigen. In these seven fami- 
lies (A-G),  six of nine haplotype homozygotes were non- 
responders, versus  none of 14 heterozygotes, a highly sig- 
nificant difference (p <  0.002). 
Families H and I, chosen because each contained a known 
nonresponder, were found to include members with the haplo- 
type [HLA-BS,SC01,DR3].  Only in these families,  where 
the proband nonresponders were [HLA-B8,SC01,DR3] het- 
erozygous, were six other heterozygotes for the haplotype 
also nonresponders. 
Linkage Analysis.  Sequential LOD scores were obtained 
for families A-E, I, and J. Three uninformative families were 
excluded from analysis:  families  F and G because they con- 
tained no nonresponder members, and family H because both 
parents and one grandparent were nonresponders. In the re- 
maining families,  the highest positive LOD score,  6.3,  oc- 
curred at a recombination fraction of 0.10. 
Antibody Levels  after Tetanus Toxoid  lmmunization.  To dem- 
onstrate that the MHC association with lack of antibody re- 
sponse to hepatitis B immunization is distinct from the lack 
of response to other vaccines,  we studied the antibody re- 
sponse to tetanus toxoid in our subjects (Table 2). Of 43 sub- 
jects, two had low initial antibody titers (1:16) but did not 
undergo booster immunization with tetanus toxoid; the other 
41 individuals either had levels of antibody to tetanus that 
were >i 1:512 at the start of the study, or else agreed to booster 
immunization with tetanus toxoid. Of these 41 subjects,  18 
were nonresponders to HBsAg; however only two of 41 had 
poor responses to tetanus toxoid. Of these two, one (a member 
of family A) had a normal antibody level after hepatitis B 
immunization, but a tetanus titer of 1:16; the other (the oldest 
member of family H) was a hepatitis nonresponder whose 
tetanus titer went from 1:16 to 1:256 after vaccination. Both 
subjects  were heterozygous for the  HLA  haplotype  [BS, 
SC01,DR3]. 
Evidence for Natural Infection with HBV in Study Subjects. 
Exposure to the natural hepatitis B virus through infection 
(as opposed to the purified S protein) was able to circumvent 
nonresponsiveness in one case report (23). We therefore looked 
for evidence of natural infection with hepatitis B virus (HBV), 
by determining the presence of antibodies to HBc, in three 
subjects (and their families) where nonresponsiveness was 
predicted, but a better-than-expected or normal antibody re- 
sponse was seen:  members of family D, where two HLA- 
identical [HLA-BS,SC01,DK3]  homozygous siblings made 
low normal amounts of antibody; family H, where an HLA- 
identical sibling of a nonresponder made a normal amount 
of antibody; and family E, where an [HLA-B8,SC01,DR3] 
haplotype-homozygous individual made a normal amount 
of antibody. We also studied family J, where one individual 
was known to have been infected with HBV. Only the pro- 
band nonresponder of family J had a high titer of anti-HBc 
(positive at a dilution of (1:100), consistent with his history 
of previous infection with HBV;  all other serum samples in 
this and the other three families were negative. 
Discussion 
Our results in this human study of immune response to 
the hepatitis B vaccine parallel those previously reported in 
murine models using the S protein.  First,  we have shown 
that the response to hepatitis B vaccine in humans is MHC 
linked, as evidenced by the LOD score of 6.3 at a recombina- 
tion fraction of 0.1.  In five families  (A,C,H,I,  and J), non- 
responders to the vaccine had an HLA-identical sibling,  for 
a total of six pairs (two pairs in family H). In five of these 
six pairs, siblings made virtually identical levels of antibody. 
In only one pair,  in family H, did one of the two [HLA- 
B44,FC31,DR7]-haplotype-homozygous individuals  develop 
an exuberant level of antibody. This subject had no antibodies 
to hepatitis B core antigen, ruling out the possibility that 
she had been previously infected with HBV, and in this way 
had circumvented her sibling's nonresponsiveness to HBsAg. 
It  is possible,  instead,  that  unidentified non-MHC-linked 
factors that enhanced T cell function nonspecifically helped 
circumvent nonresponsiveness in this case. In mice, for ex- 
ample, nonresponders of the H-2 s haplotype can be induced 
to make antibody when 10 times the dose of antigen is used 
for  immunization,  or  when  an  alternative  injection  site 
(footpad, as opposed to intraperitoneal, injection) is used (4). 
These results suggest that the B cell populations necessary 
for anti-HBs production are present in nonresponders, and 
that the absence of specific T cell help, while critical to non- 
responder status,  can be overcome. Alternatively, somatic 
changes in the MHC, undetected by our serologic tests for 
Table  2.  HBsAg Versus Tetanus Toxoid Antibodies 
HBsAg response 
Tetanus antibodies 
<1:512 
(no.  of subjects) 
>1:512 
(no.  of subjects)  Total 
Normal (>12,000 KIA U) 
None (<2,000  KIA U) 
Total 
1  22  23 
1  17  18 
2  39  41 
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or other characteristics of immune response genes, may have 
occurred in one but not the other sibling. The identification 
and location of such a change would provide key informa- 
tion about Ir genes and their function. 
Second, we have provided further proof with this study 
that individuals homozygous for  the extended haplotype 
[HLA-B8,SC01,DR3] are nonresponders to hepatitis B im- 
munization, but normal antibody responders to tetanus toxoid. 
Nine  individuals from  five different families  (A-E)  were 
homozygous for this haplotype. All nine responded normally 
to tetanus toxoid; but six were HBsAg nonresponders, and 
two had only low normal responses. Only one individual, 
in family E, was an exception in that she made a normal level 
of antibody to HBsAg (44,800 RIA U). In this family, three 
separate examples of [HLA-B8,SC01,DR3]  were present: the 
father was a haplotype-homozygous nonresponder, and the 
mother, who refused vaccination, was [HLA-BS,SC01,DR3] 
heterozygous. The daughter inherited both the maternal and 
one of the two paternal [HLA-B8,SC01,DR3] haplotypes. 
She had no detectable  antibodies to HBcAg. The presence 
of anti-HBs in this subject suggests that the maternal [HLA- 
B8,SC01,DR3] haplotype, although grossly identical with 
the paternal and other examples of this extended haplotype, 
may differ in fine structure in the region of the immune re- 
sponse gene. 
In families with [HLA-B8,SC01,DR3]  homozygotes (fam- 
ilies A-D), [HLA-BS,SC01,DR3] heterozygotes and noniden- 
tical family members all bad better antibody responses than 
their [HLA-BS,SC01,DR3]-haplotype-homozygous  relatives: 
all 10 heterozygous or nonhaplotype-bearing subjects were 
antibody responders.  These family studies support the hy- 
pothesis that the haplotype [HLA-B8,SC01,DR3]  lacks a 
normal immune response gene for HBsAg, and the immune 
defect associated with this haplotype can be overcome provided 
that an individual inherits a normal immune response gene 
on the other haplotype. 
However, [HLA-BS,SC01,DR3]  cannot be the only haplo- 
type deficient in an Ir gene for HBsAg. Based on studies of 
antibody response in normal health care workers, and assuming 
an autosomal dominant mode of inheritance of Ir genes, we 
have hypothesized that the frequency of hyporesponse genes 
to HBsAg may approach a frequency of 0.37 (12, 17). Since 
[HLA-BS,SC01,Dlk3]  has a frequency of 0.09 in Caucasians 
(13), its inheritance explains only 25% of nonresponder haplo- 
types to the vaccine in this population, and other haplotypes 
must be involved. 
We therefore studied families H, I, and J, ascertained be- 
cause a member was known to be a nonresponder to the hep- 
atitis vaccine. Consistent with our expectations, the extended 
haplotype [HLA-B8,SC01,DR3] turned out to be present in 
two of the three families (H and I). In each case, the initial 
(proband)  nonresponder was  heterozygous for  [HLA-B8, 
SC01,DR3] and another haplotype, suggesting that the second 
haplotype was also abnormal with regard to Ir gene(s) for 
HBsAg. In family H, the [HLA-BS,SC01,DR3]-heterozygous 
proband had an HLA-identical sibling who was also a non- 
responder. In addition to these two family members, six other 
individuals, spanning three generations, were nonresponders, 
suggesting that all five haplotypes in this family (two ex- 
amples of [HLA-B44,FC31,DR7],  as well as [HLA-B8,SC01, 
DR3], [HLA-B7,SC31,DR21, and [HLA-Bw60,SB42,DR4]) 
were associated with nonresponse to the vaccine. The pro- 
band nonresponder in family I, also [HLA-B8,SC01,DR3] 
heterozygous, had no HLA-identical siblings. However, her 
daughters, both heterozygotes for the proband's [HLA-B8, 
SC01,DR3] haplotype, were also nonresponders. In this family, 
two additional haplotypes appeared to have defects in the Ir 
gene for HBsAg. Since [HLA-B8,SC01,DR3] lacks an Ir gene, 
the results in these two families support our hypothesis that 
haplotypes other than  [HLA-B8,SC01,DR3]  also lack  an 
HBsAg Ir gene. 
The results in family J are consistent with the hypothesis 
that this family carries two non-[HLA-B8,SC01,DR3]-bearing 
haplotypes (a and c), each with abnormal HBsAg Ir genes. 
The initial nortresponder (a/c haplotype) had an HLA-identical 
sibling, who also proved to be a nonresponder during the 
study. A sibling haploidentical with the nonresponders (b/c) 
made a normal amount of antibody (19,168 RIA U), and 
the nonidentical sibling (b/d) was an exuberant antibody pro- 
ducer (109,600 RIA U). An alternative explanation, that the 
a haplotype carries an immune suppression gene, cannot be 
ruled out in this family, because no a/d sibling existed for 
immunization studies. If the latter hypothesis were correct, 
however, family H would be the only one, of 10 in the study, 
where an immune suppression gene could be invoked. 
Thus, our results  suggest the following conclusions in 
humans regarding immunization to HBsAg: (a) response to 
the vaccine is MHC linked, and inherited in a dominant 
fashion;  (b) an abnormal or missing Ir gene for HBsAg is 
a characteristic of most examples of the extended haplotype 
[HLA-B8,SC01,DR3], as evidenced by the lack of response 
to HBsAg immunization in nearly all individuals who are 
homozygous for this haplotype; and (c) other haplotypes also 
have abnormal or missing Ir genes for HBsAg. 
Our findings, while similar to those in mice, differ from 
the interpretation of some Japanese workers of in vivo and 
in vitro data on nonresponding oriental subjects, which they 
report as consistent with the presence of an autosomal domi- 
nant immune suppression gene on a common  Japanese haplo- 
type [HLA-Bw54,DR4,DRw53]  (24-26).  However,  some 
of these studies were based on an inferior mode of vaccine 
administration, the subcutaneous route, which resulted in a 
much higher incidence of nonresponders (22.4%)  than found 
in other studies, and may have obscured interpretation of the 
data (25,  26).  Our conclusions were based on results of a 
rigorous study protocol, which included the use of intramus- 
cular injections in the deltoid muscle, and consistent use of 
antibody determinations 2 mo after the third vaccination. 
Furthermore, no Japanese family studies were done to prove 
that suppression was inherited as a dominant trait.  Some 
groups have reported the presence of HBsAg-specific suppressor 
T cells in Japanese nonresponders (24, 25); however, we have 
been unable to demonstrate any effect of T cell suppression 
in Caucasian  nonresponders using an in vitro proliferation 
assay (27). 
500  Inheritance  of Immune Response  to Hepatitis  B Vaccine A number of  other possible associations between the [HLA- 
B8,SC01,DR3]  haplotype, or markers for it, and a variety 
of  diseases and in vitro immunologic abnormalities, have been 
reported over the years, including celiac disease (28, 29), der- 
matitis herpetiformis (30), diabetes meUitus (31, 32), alloim- 
munization to the platelet antigen PLA1 (33),  rapidity of 
progression of HIV-related illness (34, 35), abnormal in vitro 
lymphocyte proliferation in  response  to  PHA  and  other 
mitogens (36-39), and abnormal Fc receptor function (40). 
It is quite possible  that this extended haplotype has many 
aberrant Ir and other genes. Our demonstration of a clear 
relationship between the extended haplotype [HLA-BS,SC01, 
DR3] and a defective Ir gene for HBsAg was facilitated by 
the study of individuals homozygous for this extended haplo- 
type. In some of the other reports, where only heterozygotes 
were studied, or else discovered retrospectively,  the influence 
of a wide assortment of second haplotypes, and the very high 
incidence  of  the  [HLA-B8,SC01,DR3]  haplotype  in  the 
northern European Caucasian population, make conclusions 
about MHC associations  more tenuous. It is also not clear 
whether any of these additional immunologic abnormalities 
are related to the defective Ir gene for HBsAg on this haplo- 
type. Since we found normal antibody responses  to tetanus 
toxoid in all hepatitis B vaccine nonresponders who were 
haplotype homozygous for [HLA-B8,SC01,DR3], the lack 
of response to hepatitis vaccine is most likely antigen specific, 
rather than a more general problem with the immune re- 
sponse  determined by this haplotype. 
Neither the location of the Ir gene responsible  for hepa- 
titis B antibody production, nor the defect that results when 
it is missing or functioning poorly, is understood. However, 
the identification of [HLA-B8,SC01,DR3] and other haplo- 
types as MHC markers for nonresponse opens the way to 
more directed studies of HBsAg recognition and presenta- 
tion in association  with the MHC. 
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